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Abstract Degeneration of the axon is an important step in
the pathomechanism of traumatic, inflammatory and degen-
erative neurological diseases. Increasing evidence suggests
that axonal degeneration occurs early in the course of these
diseases and therefore represents a promising target for
future therapeutic strategies. We review the evidence for
axonal destruction from pathological findings and animal
models with particular emphasis on neurodegenerative and
neurotraumatic disorders. We discuss the basic morpholog-
ical and temporal modalities of axonal degeneration (acute,
chronic and focal axonal degeneration and Wallerian degen-
eration). Based on the mechanistic concepts, we then delin-
eate in detail the major molecular mechanisms that underlie
the degenerative cascade, such as calcium influx, axonal
transport, protein aggregation and autophagy. We finally





The axon represents the largest functional entity in many
neuronal populations, e.g. spanning up to more than one
meter in human motoneurons. Whereas the dysfunction of
the cell soma and its consecutive degeneration in the course
of neurological disorders dominated the perception in neu-
ropathology for many years, an increasing amount of data
supports the concept of axonal degeneration as the initial
pathological mechanism. Thus, it comes to no surprise that
many approaches aiming at neuroprotection and mainly
somatic mechanisms (not specifically targeting the axon)
have failed in functional long-term trials and in humans.
The consideration of axonal degeneration as a major mech-
anistic step is therefore mandatory for the design of success-
ful therapeutic strategies in disorders of the central nervous
system (CNS).
The discovery of mutant mice that show a delay in
Wallerian degeneration after injury through expression of
the WldS (slow Wallerian degeneration) mutant protein
(Lunn et al. 1989) prompted the idea that axonal degenera-
tion, similar to apoptosis, is a controlled mechanism that
does not occur in a random fashion but can be regulated. In
similarity to programmed cell death, conserved mechanisms
seemtoparticipateinthecourseoftraumaticanddegenerative
axonal demise. An understanding of these molecular path-
ways should therefore not only enable us to interact and
interferewithdegenerationinatrueneuroprotectiveapproach,
but also could lay grounds for regenerative attempts.
This review starts with an overview of the evidence for
axonal degeneration in pathological conditions and then
addresses the morphological and molecular processes of
axonal destruction. Finally, we summarize putative thera-
peutic strategies based on the current knowledge of molec-
ular mechanisms. Because of the wealth of data and the
rapid growth of information on the topic, we have had to
make a selection of cited works reflecting our effort to draw
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Axonal degeneration in CNS disease
Traumatic injury to the brain or to the spinal cord most
obviously involves primary axonal disruption. However,
inflammatory disorders, such as multiple sclerosis (MS),
and degenerative diseases, such as Alzheimer’sd i s e a s e
(AD) and Parkinson’s disease (PD), also show pronounced
axonal pathology. We have to bear in mind that, although
some parts of the degenerative cascade might indeed be
similar in different pathologies, their origins may vary fun-
damentally. Membrane disruption in traumatic brain or spi-
nal cord injury, for example, might eventually result in
calcium influx, calpain-mediated cleavage and axonal trans-
port breakdown. Axonal transport impairment, however,
may also be caused by aggregation of proteins. Both mem-
brane disruption and protein aggregation can thus converge
on the very same common final path having a provenance in
completely different pathologies. This illustrates that axonal
degeneration cannot be regarded as a uniform sequence of
events, but rather should be seen as a process with numerous
variants, some of which share common key features.
In the following section, we discuss the neuropathologi-
cal evidence with respect to axonal degeneration from trau-
matic, inflammatory and degenerative CNS disorders and
their corresponding animal models.
Traumatic CNS disorders
Traumatic spinal cord injury is a prime example of axonal
damage that affects the longest projecting CNS neurons and
peripheral afferents. Most cases of traumatic spinal cord
injury result in a partial transection of ascending and/or
descending tracts and incomplete impairment of sensory or
motor functions, whereas only a small fraction represents
complete transections (Rowland et al. 2008). Next to the
initial axonal damage that occurs because of mechanical
stress, secondary damage contributes to further dysfunction
(Bramlett and Dietrich 2007). Primary damage to cortical
neurons induces Wallerian degeneration of the distal axons
projecting to the spinal cord. However, in addition to this
direct lesion effect, neighbouring axons that have not been
primarily affected show signs of degeneration after a lag
period. This is accompanied by a local increase of Iba-1-
positive microglia, which are hypothesized to be responsible
for this secondary damage (Weishaupt et al. 2010).
The spinal cord lesion was also one of the first mamma-
lian animal models in which axonal degeneration could be
imaged in vivo. Selective labelling of dorsal root ganglion
neurons by using transgenic mice expressing fluorophores
in a subset of neurons allowed the visualization of degener-
ative changes within the first minutes after lesion and per-
mitted the re-imaging of animals several days later. This
pioneering technique permitted the identification of acute
axonal degeneration (see Acute axonal degeneration)a sa
separate initial mechanism following traumatic lesions
(Kerschensteiner et al. 2005).
Traumatic injury to the brain also results in pronounced
axonal lesions, mostly attributable to shear stress (Meythaler
et al. 2001). In contrast to focal spinal cord injury, axonal
damage in traumatic brain injury is more diffuse. Complete
transections are less frequent but the shear stress results in
structural damage and bead formation in the axons, which
eventually can lead to dysfunction and cell death (McIntosh
et al. 1996).
Axonal membrane permeability appears to be rapidly
altered after even moderate traumatic brain injury and this
is accompanied by a local compaction of neurofilaments
(Pettus et al. 1994). In a cat model of fluid percussion brain
injury, these local permeability alterations are apparent as
early as 5 min after trauma and the decreased spacing of
neurofilaments persists at least for 6 h after the impact
(Pettus and Povlishock 1996). Another commonly used
model for traumatic brain injury is the stretch injury para-
digm in cultured neurons in vitro. Following stretch, undu-
lating distortions are formed along the axons; these are
attributable to microtubule breakage and subsequent micro-
tubule loss. Taxol treatment is able to attenuate consequent
axonal degeneration, whereas nocodazole treatment pro-
motes it. The downstream cascades of microtubule disrup-
tion are likely to involve axonal transport dysfunction (see




Many neuropathological studies of PD brains now support
the hypothesis that the loss of striatal dopaminergic termi-
nals precedes the demise of dopaminergic neurons in the
substantia nigra pars compacta, the demise having long been
regarded as the major pathological hallmark of PD (for a
review, see Burke 2010). Consistent with this idea, striatal
dopamine levels decrease more strongly than the numbers of
nigral dopaminergic neurons in PD patients (Kish et al.
1988). Remarkably, the first observable changes in early
stage PD brains involve the appearance of Lewy neurites,
which initially outnumber Lewy bodies localized in the
dopaminergic cell soma (Braak et al. 2003). The axonal
projections of the substantia nigra relay an inhibitory signal
via dopaminergic transmission to the striatum. However,
290 Cell Tissue Res (2012) 349:289–311whereas the degeneration of this anatomical projection most
prominently reflects the negative motor symptoms in the
disease, it is indeed not the only fiber tract affected by
degenerative pathology; as could be demonstrated by the
studies of Braak and colleagues (2003), degenerative
changes appear first in the dorsal motor nucleus of the vagal
nerve, spreading further via the caudal raphe nuclei and
nucleus coeruleus before reaching the midbrain. Synaptic
dysfunction attributable to axonal pathology in the hippo-
campus and the amygdala of PD patients has been implicat-
ed in cognitive and emotional impairment in this disease
(Bertrand et al. 2003). More recently, Orimo et al. (2008)
have evaluated the degeneration of cardiac sympathetic
nerves, which degenerate in PD and in Lewy body disease.
Moreover, here, distal axonal degeneration precedes the loss
of their mother neurons. Interestingly, alpha-synuclein
aggregates are even more frequent in incidental Lewy body
disease, in which tyrosine-hydroxylase-positive neurons are
still preserved, than in PD patients, which further ferments
the discussion of whether Lewy bodies per se are toxic or
even protective in aggregopathies. Here, aggregates are
predominantly found in the neuronal soma but the number
of axons has already decreased markedly (Orimo et al.
2008). These observations in patients with idiopathic PD
are similar to those in a brain of a familial PD patient
carrying the alpha-synuclein (A30P) mutation (Seidel et al.
2010b). In addition to the degeneration of the nigrostriatal
axonal projections, PD patients also show trans-synaptic
degeneration, e.g. in the caudate nucleus. This has been made
responsibleforthepoorclinicalresponseofadvancedstagePD
patients to dopaminergic graft therapy (Lach et al. 1992).
This wealth of data suggests that, in PD, the initially
occurring axonal pathology precedes neuronal cell death
and that axonal degeneration is the histological substrate
of clinically apparent motor and non-motor deficits.
Animal models based on genetic PD forms and toxin-
based paradigms also suggest an involvement of axonal
pathology in the beginning of the disease process. In a rat
model of PD based on adeno-associated virus (AAV)-
mediated expression of mutant human alpha-synuclein
(aSyn.A53T) in the substantia nigra, neuronal loss occurs
in a significant manner after 17 weeks. However, well
before that, as early as 4 weeks after AAV-injection, dystro-
phic dopaminergic neurons in the striatum are found and a
marked change occurs in proteins with functions in synaptic
transmission and axonal transport (Chung et al. 2009).
Axonal transport impairment (see Axonal transport) has also
been observed in cultured neurons transfected with mutant
forms of alpha-synuclein in vitro (Saha et al. 2004). Next to
the overexpression of alpha-synuclein, the application of the
neurotoxin 1-methyl-4-phenylpyridinium (MPP
+)t op r i m a r y
dopaminergic neurons also leads to significant alterations of
axonal transport mechanisms in vitro. Interestingly, MPP
+
shows effects on mitochondrial movement, but not on
synaptophysin-tagged vesicles or other moving particles,
demonstrating that substrate specificity contributes to the par-
ticular toxicity of MPP
+ in axons. In this model, neurite
degeneration and an induction of autophagy (see Autophagy
and the ubiquitin-proteasome system) also occur before cell
body loss (Kim-Han et al. 2011).
Autosomal-dominant mutations in leucine-rich repeat
kinase 2 (LRRK2) belong to the most frequent causes of
familial PD. Large genome-wide association studies have
identified LRRK2 in addition to alpha-synuclein as an
important risk locus for the development of PD (Simón-
Sánchez et al. 2009; Satake et al. 2009). Even the initial
reports of LRRK2 function implied a role in neurite growth
for this large multidomain protein (Macleod et al. 2006). In
Drosophila, overexpression of the pathogenic LRRK2
(G2019S) mutant results in mislocalization of tau protein
in dendrites and causes dendrite degeneration. The mecha-
nism is suggested to involve an increased recruitment of the
Drosophila glycogen synthase kinase 3 (GSK-3β) homolog
(shaggy) by LRRK2 (G2019S), which in turn induces
hyperphosphorylation and mislocalization of tau (Lin et al.
2010). Overexpression of the human mutant LRRK2
(R1441G) in a bacterial artificial chromosome transgenic
mouse model supports the role of this protein in axonal
stability. In addition to levodopa-sensitive motor symptoms,
which have been observed at 10 months of age, these
animals present fragmented dopaminergic axons, axonal
spheroids and dystrophic neurites (Li et al. 2009). As can
also be shown in SH-SY5Y cells in vitro, overexpression of
mutant LRRK2 (G2019S) results in decreased neurite out-
growth and an increased number of autophagic vacuoles
(see Autophagy and the ubiquitin-proteasome system) and
this effect is mediated by mitogen-activated protein kinase
(MAPK)/extracellular signal-regulated kinase (ERK) signal-
ling (Plowey et al. 2008).
Models based on alpha-synuclein, LRRK2 or 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/MPP
+ appear
substantially different at first glance and all these models
only partially reproduce the pathophysiology of human PD.
However, alterations in axonal transport, autophagy and an
early axonal loss preceding cell death seem predominantly
common themes that can be partially correlated to autopsy
material suggesting an involvement of these processes in the
human disease. Thus, the hope is raised that the targeting of
any of these mechanisms in a therapeutic manner will mod-
ify the disease progression in humans independently of the
underlying etiology.
Amyotrophic lateral sclerosis
Axonal degeneration in amyotrophic lateral sclerosis (ALS)
has long been considered to occur only as a secondary
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Wallerian degeneration (Przedborski 2004). Thus, the
“dying-forward” hypothesis proposes that ALS is mainly a
disorder of cortical motoneurons that connect monosynapti-
cally with anterior horn cells and mediate anterograde degen-
eration of anterior horn cells via glutamate excitotoxicity.
However, several animal studies have recently demonstrated
that the exclusive protection of the neuronal cell body, e.g.
through the regulation of pro- or anti-apoptotic proteins such
as Bax or Bcl-2, does not prevent axonal degeneration or
functional deterioration (Sagot et al. 1995; Gould et al.
2006). Even stronger evidence comes from human autopsy
material. Fischer and colleagues (2004) have impressively
demonstrated, in autopsy material from an ALS patient who
died from an unrelated cause only 6 months after symptom
onset, that denervation and reinnervation were pronounced,
while the spinal motor neurons were not yet affected. Patho-
logical examination of tissue from ALS autopsy cases and
fromtransgenicmousemodelsofthediseasedemonstratesthe
appearance of swollen axonal segments or spheroids being
rich in intermediate filament proteins including the neurofila-
menttriplet proteinsNFL, NFM and NFH (Hirano 1996).The
pathophysiology that leads tothe formation ofthese spheroids
is most likely linked to axonal transport deficits (see Axonal
transport) as has been shown in various mouse models (Rao
and Nixon 2003). Recently, data from a cell culture model of
axonopathy with spheroid formation, neurofilament and
microtubule disorganization have underlined the important
influence of the glial environment on the disruption of axonal
transport (King et al. 2011). Hence, (1) the mechanisms of
neuronal cell body demise must differ from axonal degenera-
tion and the latter cannot be explained as a pure consequence
of the somatic dysfunction and (2) axonal degeneration seems
to precede neuron death in this disease, suggesting an addi-
tional “dying back” mechanism (for reviews, see Rowland
and Shneider 2001; Fischer and Glass 2007).
This is also reflected in the SOD1 (G93A) mouse model
of ALS, which is based on a mutation found in familial ALS
cases and faithfully reproduces the clinical course of disease
in humans (Gurney et al. 1994). Because of a clearly defined
age at symptom onset, SOD1 (G93A) mice are an ideal
model for the study of the presymptomatic alterations in
this motoneuron disorder. Paralleling the findings from
autopsy material, SOD1 (G93A) mice show a dramatic
denervation of motor end plates well before the onset of
clinical disease; whereas motor weakness starts to be appar-
ent only at around 80 days, about 40% of the neuromuscular
junctions show denervation. However, at this time, no
evidence for motoneuron cell loss is detectable (Fischer
et al. 2004). The situation seems to be slightly different for
corticospinal motoneurons. In the same SOD1 (G93A) mod-
el, early and cell-type specific apoptosis has been observed
among neocortical neurons. Here, the degeneration of the
corticospinal tract appears to follow neuronal demise, which
can be visualized by using double-transgenic Thy1-YFP/
SOD1 (G93A) mutants (Ozdinler et al. 2011). A recent study
by Bilsland et al. (2010) clearly demonstrates that axonal
transport deficits occur in presymptomatic mice and represent
the earliest axonal pathologies in this model, occurring well
before motoneuron loss.
In conclusion, data from ALS and motoneuron disease
models suggests that axonal degeneration probably precedes
motoneuron death. This obviously does not exclude the
presence and negative additional impact of somatic dysfunc-
tion on disease progression.
Alzheimer’s disease
One of the prominent neuronal structural alterations in
AD, other than amyloid plaques and neurofibrillary tangles,
are dystrophic neurites (Onorato et al. 1989). These neurites
are characterized by the disorganization of the microtubule
and the neurofilament network (Boutajangout et al. 2004)a n d
the abnormal accumulation of variably phosphorylated
neurofilaments that can be found even in early stages of
the disease (Dickson et al. 1999). A recent study in
human patients with mild cognitive impairment and
early AD has visualized functionally relevant alterations
of the axonal tracts in the white matter of the brain by
employing diffusion tensor imaging, thereby confirming
that axonal degeneration is a measurable pathological
feature even at early stages of this disease in humans
(Huang et al. 2007).
Moreover, a number of animal models for AD have been
developed and extensively studied as a surrogate for neuro-
pathological alterations observed in human patients. Pro-
nounced axonal degeneration has been reported for most
of these models, including models with underlying muta-
tions of tau (Probst et al. 2001), ApoE (Tesseur et al. 2000),
and amyloid precursor protein (APP; Wirths et al. 2007), to
name only a few examples. These axonal defects are typi-
cally characterized by large axonal swellings, often in close
proximity to the amyloid plaques (Stokin et al. 2005). For
example, in 5XFAD mice expressing a triple-mutated
human APP, prominent axonal swellings are found in
the brain and spinal cord even at 3 months of age
(Jawhar et al. 2010). Many dystrophic neurites can be
seen close to extracellular plaques. The motor deficits
observed in these mice correlate with the formation of
axonal spheroids in the brain and spinal cord (Oakley et
al. 2006;J a w h a re ta l .2010). The interaction of extra-
cellular plaques and the intra-axonal milieu is a matter
of intense current research and a better understanding of
this interaction might shed light on the function of
protein aggregates for axonal degeneration in a number
of aggregopathies.
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For decades MS, as the prime example for chronic inflam-
matory CNS disorders, has been regarded as a largely
demyelinating disorder. However, studies of brain tissue
from MS patients have changed this picture completely;
axonal transections with morphological changes resembling
traumatic axonal injury, such as axonal ovoids, are abun-
dantly present in acute and chronic lesions (Ferguson et al.
1997;T r a p pe ta l .1998). Characteristics of Wallerian
degeneration can be identified in the periplaque white matter
in early MS, reaffirming the finding that axonal lesions
represent the morphological correlate of the persistent neu-
rological deficits in MS patients (Dziedzic et al. 2010).
Animal models of MS, such as the experimental autoim-
mune encephalomyelitis (EAE) model induced by immuni-
zation with myelin oligodendrocyte glycoprotein, show
axonal degeneration as an important feature and this can
even precede the demyelinating component (D. Wang et al.
2005). Using multiphoton in vivo imaging techniques, Nikić
et al. (2011) have been able to demonstrate that focal axonal
degeneration (FAD, see Chronic axonal degeneration) might
precede demyelination in a mouse model of MS. Focal intra-
axonal mitochondrial alterations can be observed, even
before the ultrastructural signs of axonal damage. In this
model, reactive oxygen and nitrogen species, which are
likely to be derived from activated macrophages, are able
to initiate mitochondrial damage and FAD. Most intriguing-
ly, the authors have been able to show that these initial
axonal alterations can be reversible up to a certain time
point, opening a novel window for intervention. Similar
changes have also been observed in human biopsy tissue
of MS patients underlining the importance of these findings
(Nikić et al. 2011).
Mechanisms of axonal degeneration
In this section, we will first describe basic concepts of
axonal demise; these concepts are initially described based
on their morphological and temporal characteristics. Sec-
ondly, we will take a closer look at the molecular mecha-
nisms underlying axonal damage, thereby making clear that
such mechanisms can represent underlying events of mor-
phologically different degenerative processes.
Mechanistic concepts
Like apoptosis, most forms of axonal degeneration seem to
be active self-destructing cellular processes involving a
determined cascade of various molecular players (Raff
et al. 2002). We need however to note that apoptosis and
axonal degeneration employ independent biochemical
pathways and can be initiated and modulated separately
(Whitmore et al. 2003). Different forms of axonal degenera-
tion have been described with regards to localization on the
axon and time kinetics. Although common molecular conver-
gence points probably exist, important mechanistical differ-
ences are found between each type of axonal degeneration.
The most extensively studied form of axonal degeneration is
the sequential degeneration following a traumatic lesion of an
axon. This includes acute axonal degeneration in the vicinity
of the lesion and Wallerian degeneration of the distal part of
the axon. The study of axonal degeneration in chronic neuro-
logical diseases represents a greater challenge as this process
does not occur simultaneously in all axons of a certain tract
and often proceeds over extended time periods. Nevertheless,
FAD, axonal die-back and Wallerian degeneration have been
described for these conditions.
Acute axonal degeneration
The term acute axonal degeneration refers to a rapid axonal
disintegration within several hours following a traumatic
lesion in the CNS. It is confined to the adjacent 300–
400 μm of the proximal and distal end of the axon and has
been described for the spinal cord (Kerschensteiner et al.
2005) and the optic nerve (Knöferle et al. 2010). In both
cases, it has been visualized by using in vivo live-imaging
techniques. Although the time kinetics differ slightly be-
tween the model systems, being faster in the mouse spinal
cord than in the rat optic nerve, the sequential morpholog-
ical changes and the undelying mechanisms seem to be
similar in both tissues (summarized in Fig.1).
At first, for 10–30 min after a traumatic lesion, the axon
remains completely stable with regard to its macroscopic
morphological appearance. On the molecular level, however,
a signalling cascade has already been activated, finally result-
ing in the fragmentation of the axon. It is initiated by a rapid
calciuminfluxintotheaxonandaconsecutivetransientriseof
the axoplasmic calcium concentration within 40 s after lesion
(see Calcium). Application of calcium channel inhibitors at
the time of the lesion blocks this rise in cytosolic calcium and
almost completely inhibits acute axonal degeneration
(Knöferle et al. 2010). The calcium influx leads to an activa-
tion of the calcium-sensitive protease calpain, which reaches
its maximum 30 min after the lesion. Local application of
calpain inhibitors can completely inhibit consecutive acute
axonal degeneration (Kerschensteiner et al. 2005). Calpain
regulates a multitude of neuronal substrates (for a review,
see Vosler et al. 2008) but which of these are most relevant
for axonal degeneration is currently still under investigation
(see Calcium-triggered events).
The first changes at the ultrastructural level become
visible within the first 30 min after lesion and consist of
the condensation and misalignment of neurofilaments
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al. 2010). Both focal neurofilament compaction and micro-
tubular proteolysis have been linked to calpain activation in
other disease models in the CNS, and the ERK/MAPK
pathways have been suggested as molecular mediators
(Pettigrew et al. 1996; Veeranna et al. 2004). Therefore,
the initial calpain activation might also be responsible for
these early ultrastructural changes in acute axonal degener-
ation. Moreover, the rapid breakdown of the cytoskeleton
probably leads to the early impairment of axonal transport.
Indirect signs in favour of this assumption are accumula-
tions of organelles, mainly mitochondria and vacuoles,
eventually leading to local axonal swellings that can be
found early in axons undergoing acute axonal degeneration
(Knöferle et al. 2010).
Another characteristic ultrastructural feature of acute
axonal degeneration is a local activation of autophagy (see
Autophagy and the ubiquitin-proteasome system). The
number of autophagosomes in the axon significantly
increases within the first 6 h after lesion. Pharmacological
inhibition of autophagy markedly attenuates acute axonal
degeneration but this effect, however, is not as pronounced
as after calcium channel blockage. The latter not only inhibits
acute axonal degeneration, but also reduces autophagy,
suggesting that autophagy is a downstream target of calcium
influx (Knöferle et al. 2010;K o c he ta l .2010).
Whereas pharmacological interventions such as the inhi-
bition of calcium, calpain and autophagy are highly effec-
tive in preventing acute axonal degeneration, the long-term
effects of these treatments are still unclear. As acute axonal
Fig. 1 a Micrographs of a rat
optic nerve axon labelled with
enhanced green fluorescent
protein expressed by an
intravitreally injected viral
vector at given time points
(in min) after optic nerve crush
(proximal to the crush site). b
Quantification of the axonal
integrity ratio (sum length of
the remaining axonal fragments
divided by initial length of the
intact axon segment) of the
axon in a. c Representation of
the morphological events
observed in acute axonal
degeneration. A crush lesion of
an axon of the central nervous
system leads to a rapid increase
of intracellular calcium
concentrations within the first
30-40 s after lesion. Misalign-
ment of neurofilaments and
disruption of microtubules fol-
lowed by local accumulations
of organelles attributable to
dysfunctional axonal transport
and the subsequent formation of
axonal bulbs can be seen within
the next 30-120 min. This
is then followed by the
appearance of a high number of
autophagic vacuoles and the
fragmentation of the axon
spanning over 400 μm proximal
and distal from the crush site
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mal to the lesion site, the direct functional benefit of
rescuing this short portion of the axon is negligible.
Nevertheless, one can argue that the regenerative
response of a lesioned axon might be fostered as the
distance to the rapidly forming, growth-inhibiting scar
tissue becomes smaller. Kerschensteiner et al. (2005)
have shown that regenerating sprouts can be seen within
24 h after lesion. Although these early axonal sprouts
lack appropriate directional information, they could possibly
benefit from an inhibited acute axonal degeneration; this
however remains to be experimentally established.
Wallerian degeneration
Wallerian degeneration classically refers to the degeneration
of axons distal to a lesion site (Waller 1850). After a trau-
matic lesion, the parts of the axon that are not affected by
acute axonal degeneration initially stay morphologically
stable for the first 24 to 72 h. Then, the distal part of the
axon undergoes a progressive fragmentation that resembles
the fragmentation seen in acute axonal degeneration
(Kerschensteiner et al. 2005) and that finally leads to a
complete removal of the distal part of the axon. Wallerian
degeneration proceeds directionally along the axon with a
speed ranging from 0.4 mm/h in cultured primary neurons
(Sievers et al. 2003) to 24 mm/h in the mouse sciatic nerve
(Beirowski et al. 2005). In the peripheral nervous system,
the direction of Wallerian degeneration on the axon seems to
depend on the lesion type; complete transection of the nerve
leads to an anterograde fragmentation proceeding from
proximal to distal, whereas a crush lesion results in retro-
grade fragmentation starting at the far distal end of the axon
(Beirowski et al. 2005). Although macrophages and glia
play an important role, especially in the final removal of
the axon fragments, the mechanism of Wallerian degenera-
tion seems to be intrinsic to the axon (Glass et al. 1993;
Hoopfer et al. 2006; MacDonald et al. 2006).
The molecular machinery underlying Wallerian degener-
ation is still not completely understood, although great
progress has been made with the help of the so-called WldS
mouse (Lunn et al. 1989). In this mouse mutant, axon
stumps distal to the lesion site survive ten times longer than
axons in wild-type animals, while the survival of the neuro-
nal cell body is not altered (Deckwerth and Johnson 1994;
Adalbert et al. 2006).
The mutantprotein WldS, whichisresponsible for slowing
down the degenerative process in WldS mice, is a chimeric
gene product consisting of a fragment of the polyubiquitina-
tion factor UFD2a/UBE4b and the full-length nicotinamide
mononucleotide adenylyltransferase-1 (NMNAT1; Mack
et al. 2001). NMNAT1 is a key protein of the nicotinamide-
adenine dinucleotide
+ (NAD
+) salvage pathway in mammals.
UBE4b is an E4-type ubiquitin ligase that can add multi-
ubiquitin chains to substrates of the ubiquitin/proteasome
degradation pathway (Hatakeyama et al. 2001). The function-
ally most important molecular sites of WldS are the ATP-
binding site and the NMN
+ binding site of NMNAT1 and
the valosin-containing protein (VCP)-binding site of UBE4b,
as has been shown by knock-out experiments. Both a func-
tionalNMNAT1and afunctionalUBE4bfragmentseemtobe
required for the neuroprotective action of WldS. This is sug-
gested by the observation that, although disruption of the
enzymatic activity of NMNAT1 in transgenic WldS mice
results in a strongly reduced neuroprotective phenotype
(Avery et al. 2009;C o n f o r t ie ta l .2009; Yahata et al. 2009),
the overexpression of NMNAT1 alone is not sufficient to
protect lesioned axons from degeneration in mammalian neu-
rons (Conforti et al. 2009). Moreover, NMNAT-1 has been
demonstratedtofunctionnot onlywithenzymatic activity, but
also as a chaperone, at least in biochemical assays and cul-
tured cells (Zhai et al. 2003).
The WldS protein is located mainly in the nucleus but has
also been detected in the axoplasm and axoplasmic organ-
elles (Beirowski et al. 2009; Yahata et al. 2009). Local
overexpression of NMNAT1 targeted to the axonal compart-
ment results in protective effects resembling those of the
WldS transgene (Beirowski et al. 2009; Sasaki et al. 2009a;
Babetto et al. 2010). These data suggest that the protective
action of WldS is mediated by the continuous transport of
the protein along the axon. In agreement with this, other
NMNAT isoforms have been shown to promote axonal
survival locally. NMNAT2 is continuously transported from
the cell body to the axon and has an extremely short turn-
over time of∼4 h (Gilley and Coleman 2010). Short inter-
fering RNA (siRNA)-mediated downregulation of NMAT2
or inhibition of its transport to the axon lead to the induction
of axonal degeneration, whereas overexpression delays
axotomy-induced degeneration (Gilley and Coleman 2010;
Yan et al. 2010). Similar positive effects on axonal survival
and integrity can be achieved by the overexpression of the
mitochondrial isoform NMNAT3 (Avery et al. 2009; Yahata
et al. 2009). The downstream targets of the NMNAT iso-
forms for promoting axonal survival still remain elusive. All
NMNATs contain a catalytic domain for the synthesis of
NAD
+ (Berger et al. 2005). The data concerning the role of
NAD
+ in the maintenance of axonal survival are however
inconsistent. Extracellular application of high concentra-
tions of NAD
+ result in the protection of injured axons in
vitro, whereas various attempts to increase the intracellular
NAD
+ concentration have not had an effect on axonal
degeneration (Sasaki et al. 2009b). The local action of
NAD
+ in subcellular departments within the axon involving
local energy supply (J. Wang et al. 2005), the local seques-
tering of Ca ions or the modulation of ion channel activity
(Tamsett et al. 2009) have been argued to account for
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+-mediated effects in the axon but these hypotheses
still need to be established by experimental evidence.
Chronic axonal degeneration
The time kinetics of axonal degeneration in chronic neuro-
degenerative diseases are more challenging to study. How-
ever, various morphological forms of axonal degeneration
have been described for these conditions that may also occur
in parallel.
The first type is termed “dying back degeneration”
(Cavanagh 1964). This form of degeneration has been
described in ALS (Sobue et al. 1983; Nihei et al. 1993),
diffuse Lewy body disease (Iseki et al. 1998), spinocerebel-
lar ataxia (Seidel et al. 2010a), peripheral neuropathies
(Vavlitou et al. 2010) and toxic neuropathies (Bennett
et al. 2011), amongst others. It is initiated by a dysfunction
of the synaptic connection and/or a degeneration of the
distal regions of the axon. This is then followed by a
degeneration of the whole axon in a distal-to-proximal
direction, finally leading to a fragmentation of the axon
morphologically resembling that of Wallerian degeneration
(Cavanagh 1979). The biochemical mechanisms underlying
this form of degeneration are currently not completely clear
but synaptic pathology (Chang et al. 2006), mitochondrial
dysfunction (Shi et al. 2010) and disturbances of axonal
transport (Morfini et al. 2007; Bilsland et al. 2010) have
been implied.
Dying back degeneration shares striking similarities with
axonal pruning and axosome shedding, a process that is
observed for example in the developmental maturation of
the neuromuscular synapse or target selection, e.g. by retinal
ganglion cell axons (for excellent reviews, see Luo and
O’Leary 2005; Misgeld 2011).
Another form of axonal degeneration has been recently
visualized in a model of chronic inflammatory disease:
FAD. Morphologically, a focal swelling of the axon is
observed at the beginning and is characterized by an accu-
mulation of organelles and dysmorphic mitochondria. This
focal swelling is accompanied by a dysfunction of axonal
transport and eventually leads to a local disruption of the
axon followed by a Wallerian-like fragmentation of the axon
stumps. FAD has recently been imaged in vivo in an animal
model of MS (Nikić et al. 2011). In this EAE model,
increased levels of reactive oxygen species in the inflam-
matory EAE lesions are able to induce focal axonal swel-
lings and these have been shown to be partially reversible
(see Chronic inflammatory CNS disorders).
The underlying molecular machinery
Acute axonal degeneration, focal axonal degeneration and
Wallerian degeneration appear to be specific morphological
expressions of a cumulative number of underlying molecu-
lar mechanisms. We review here some of the most important
and so far best-characterized molecular mechanisms that
form the backbone of the degenerative cascade (summarized
in Fig. 2).
Calcium
Several means have been experimentally shown to contrib-
ute to the elevation of axoplasmic calcium concentration in
various lesion paradigms: (1) calcium influx from the extra-
cellular space through disrupted membranes, (2) calcium-
channel-mediated calcium influx from the extracellular
space and (3) release of calcium from intracellular calcium
stores (for a comprehensive review, see Stirling and Stys
2010).
Mechanical axonal lesions result in the disruption of the
membrane continuity and subsequent influx of extracellular
calcium into the cytoplasm. As Ziv and Spira (1995) have
demonstrated using calcium-sensitive dyes in cultured Aply-
sia axons in vitro, the calcium wave induced through the
transection of one neurite branch rapidly spreads, within
seconds, until the next branching point where it seems to
be halted. Intra-axonal calcium concentrations decrease sub-
sequently within several minutes reaching initial levels after
the resealing of the lesioned axon end. However, intracellular
calcium concentrations reach a maximum of up to >1 mM
near the lesion site and of up to several hundred micromolar
more distal from it (Ziv and Spira 1995). Axotomy-induced
calcium increase in vitro has been shown to require extra-
axonal calcium levels of >200 μM and calcium has been
demonstrated to enter axons via L-type, but not N-type
calcium channels in dorsal root ganglion axons (George
et al. 1995). Studies of the rat optic nerve however have
suggested the additional involvement of other calcium chan-
nels(P/Q-type,N-type)inthemediationofcalciuminfluxinto
the lesioned axon (Fern et al. 1995;A l i xe ta l .2008), suggest-
ing that the results depend on the examined region of the
nervous system.
The extra-axonalspace appears tobenot the onlysourceof
calcium, as has been demonstrated by studies employing a
calcium-depleted extracellular medium. Here, axonal damage
canequallyelicitanintra-axonalcalciumincreasedemonstrat-
ing that intracellular calcium stores can also contribute to
cytoplasmic calcium release. For example, in ischaemic
damage of dorsal column axons, calcium has been shown to
be released from the endoplasmic reticulum through ryano-
dine receptors (Ouardouz et al. 2003)o rf r o mm i t o c h o n d r i a
(Nikolaeva et al. 2005).
In myelinated axons, ryanodine receptors can be activated
through L-type Ca channels, similar to so-called excitation-
contraction coupling in skeletal muscle cells. Both ryanodine
receptors and L-type Ca channels seem to be colocalized near
296 Cell Tissue Res (2012) 349:289–311the axolemma of myelinated axons.However, the blockage of
intra-axonal calcium release, e.g. through the L-type calcium
channel blocker nimodipine, only partially protects axons
from degeneration suggesting that other sources of calcium
or other non-calcium-dependent mechanisms contribute to
axonal degeneration (Ouardouz et al. 2003). For example,
intra-axonal calcium levels are known to increase when an
ischaemia- or hypoxia-induced lack of energy supply results
in the breakdown of the Na
+/Ca
2+ exchanger (Stys et al.
1992). In ischaemia, the majority of the intra-axonal calcium
releaseappears to bemediatedthrough the Na
+/Ca
2+ exchanger
as can be demonstrated in experiments with CGP37157, a
blocker of the Na
+/Ca
2+ exchanger in mitochondria (Nikolaeva
et al. 2005). In this model, the application of cyclosporine A, a
blocker of the mitochondrial permeability transition pore
(mPTP),doesnotprovidesufficient protection,therebyarguing
against mPTP involvement. However, as Barrientos et al.
(2011) have recently demonstrated in another model, the last
word on the role of mPTP in axonal demise has not yet been
spoken; axons in optic nerve explants show less mitochondrial
swelling after the application of cyclosporine A and are
indeed protected from degeneration. This effect has been
further pinned down to the function of cyclophilin D
(CypD), a component of the mPTP in neurons, the
axons of which are protected after siRNA-mediated
depletion of CypD (Barrientos et al. 2011).




calcium levels can rise by the
entry of calcium from the
extra-axonal space, e.g. through
calcium channels and disrupted





such as calpain, are activated
and cleave target proteins, e.g.
microtubules or collapsin
response mediator protein-2
(CRMP-2). This in turn can
result in axonal transport
impairment. Autophagy is
induced in a calcium-dependent
manner and results in the
degradation of proteins and
organelles
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membrane-located pumps, such as the plasma-membrane
calcium ATPase isoform 2. A decrease in the levels of this
pump can promote axonal pathology in animal models of
MS (EAE) and spinal cord injury (Nicot et al. 2003;
Kurnellas et al. 2005).
Calcium-triggered events
Calcium influx is followed by the activation of calcium-
dependent proteases, such as calpains, which cleave and
degrade cytoplasmic proteins. An increased activity of
calpains has been demonstrated for diffuse axonal injury
following brain trauma and also in stroke, spinal cord injury
and neurodegenerative diseases (Kampfl et al. 1996; Vosler
et al. 2008). Calpains can proteolytically degrade a plethora
of targets, such as cytoskeletal proteins, enzymes, receptors,
channels and transcription factors (for a review, see Saatman
et al. 2010). As such, calpains have also been shown to
degrade substrates of crucial importance to axonal stability.
Neurite degeneration as a result of growth factor deprivation
(e.g. of nerve growth factor) also leads to calpain
activation. This is followed by proteolytic cleavage of the
collapsin response mediator protein-2 (CRMP-2; Touma
et al. 2007). Because CRMP-2 binds to kinesin-1 and par-
ticipates in axonal transport, cleavage by calpain interferes
with cargo delivery (see Aggregation under Therapeutic
targets).
In addition to calpain, other calcium-dependent enzymes
are known to participate in axonal degeneration. For exam-
ple, transient axonal stretch injury in vitro results in calcium
release primarily from intracellular stores and this is
followed by a delayed intracellular calcium level rise over
48 h. Here, the inhibition of the calcium-dependent phos-
phatase calcineurin attenuates secondary axonal degenera-
tion (Staal et al. 2010). Calpain and calcineurin are only two
examples of calcium-dependent proteins that act further
downstream and that have been studied in more detail in
this context.
Mitochondrial damage
Mitochondria appear to take a key role in the initial locali-
zation of axonal continuity disruption. In models of trau-
matic brain injury in which diffuse axonal injury is a major
pathophysiological component, calcium influx is thought to
be mediated through axolemmal pores. However, axonal
damage and calpain activation does not occur simultaneous-
ly over the entire length of the axon but shows focal peaks
colocalizing with mitochondria (Kilinc et al. 2009). This
focal accumulation of mitochondria might be attributable
to focal disruption of the cytoskeleton and cargo accumula-
tion but could equally contribute to a further focal increase
in calcium levels from accumulating mitochondria (see
Calcium).
In FAD, mitochondria are damaged by reactive oxygen
and nitrogen species, which are likely to be derived from
macrophages, and this again triggers further axonal degener-
ation (Nikić et al. 2011). As mentioned earlier (see Calcium),
the activation of the mPTP seems to play a pivotal role in
triggering axonal destruction in axons of the CNS and periph-
eral nervous system (PNS) axons (Barrientos et al. 2011). In a
model of familial ALS, mitochondria seem to participate in
apoptotic cell death and consequent axonal degeneration,
because the deletion of two neuronal pro-apoptotic Bcl-2
family members, Bax and Bak, is able to prevent axonal
degeneration (Reyes et al. 2010). The debate on the relevance
of mitochondrial motility is not completely settled as yet,
since reports have alsodemonstrated that increased mitochon-
drial transport, as observed in syntaphilin knock-out mice,
does not support survival in the SOD1 (G93A) mouse model
(Zhu and Sheng 2011). On the other hand, motility impair-
ment has been shown in a model of Huntington’sd i s e a s ei n
which mutant huntingtin interacts with the mitochondrial pro-
tein Drp1 and results in defective mitochondrial movement
and synaptic deficiencies (Shirendeb et al. 2011). Amyloid-
beta (Aβ) has recently also been shown to impair mitochon-
drial motility and neurons treated with Aβ have shorter mito-
chondria, a feature that eventually results in synaptic
degeneration (Calkins and Reddy 2011). Even more evidence
comes from a histological study in brain samples of MS
patients with chronic and active lesions in which alterations
in mitochondrial density and function have been detected.
Here, the activity of the mitochondrial respiratory chain com-
plex IV has been shown to be reduced in demyelinated axons
attheactiveedgeofchronicactivelesionsbut,interestingly,in
chronic lesions, complex IVactivity and mitochondrial mass
are increased, possibly because of adaptive processes occur-
ring during disease progression (Mahad et al. 2009).
The above-mentioned findings are only a few examples
underlining that alteration of mitochondrial function, mito-
chondrial trafficking and activation of the mitochondrial
apoptotic pathway, all of which might contribute to axonal
damage in the different contexts of CNS pathology. A local
lack of energy supply attributable to mitochondrial failure
and a local increase of calcium concentrations might both be
crucial factors.
Aggregation
Amyloidogenic proteins, such as alpha-synuclein, tau and
Aβ, have been suggested to promote axonal degeneration in
several neurodegenerative disorders, e.g. through interfer-
ence with axonal transport mechanisms. Of course, the
aggregation of proteins does not occur in all paradigms of
axonal degeneration but it may promote axonal pathology in
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wild-type alpha-synuclein by lentiviral vectors has recently
been shown to result in aggregation and a clear degenerative
phenotype in CNS axons (Decressac et al. 2011). Aggrega-
tion of amyloidogenic proteins cannot be regarded as a
stand-alone phenomenon, since recent data have demon-
strated that increased calcium concentrations accelerate
alpha-synuclein aggregation in solution and in cultured cells
(Nath et al. 2011). Thus, we can hypothesize that axonal
lesions with consequent calcium influx also drives the
aggregation of amyloidogenic proteins. Vice-versa, the pres-
ence of alpha-synuclein itself appears to influence trauma-
induced axonal degeneration. Transgenic mice overexpress-
ing the human alpha-synuclein (Thy1-αSynWT)p o s s e s s
alpha-synuclein aggregates in the axons of the sciatic nerve.
These animals display increased Wallerian degeneration
after axotomy of the sciatic nerve, whereas in mice without
alpha-synuclein expression (C57BL/6-Ola-hsd strain by
Harlan B6), axonal degeneration occurs at a significantly
slower rate (Siebert et al. 2010). This is intriguing, because
alpha-synuclein is predominantly attributed a function in
neurodegeneration of the CNS. This study, however, sug-
gests that alpha-synuclein is involved in a more general
mechanism of axonal destruction, which is also important
for the PNS and traumatic lesions, and might be independent
of a chronic neurodegenerative process per se. Its precise
mode of action is as yet unresolved but accumulating data
have led to the proposal of a direct interaction with the
cytoskeleton; the colocalization of alpha-synuclein has been
reported not only with cytoskeletal proteins, such as neuro-
filaments, tau and tubulin (Jensen et al. 1999; Alim et al.
2002; Kanazawa et al. 2008), but also for transport proteins,
such as dynein and kinesin-1 (Utton et al. 2005).
Axonalinclusionshavealsobeenfoundinbrainsofpatients
with spinocerebellar ataxia type-3 (SCA3). Ubiquitin-positive
aggregates have been observed in axonal projections that are
known to degenerate in SCA3 patients. It is likely that these
aggregates are detrimental to axonal transport mechanisms;
this however remains to be established (Seidel et al. 2010a).
Similar evidence comes from animal models of Huntington’s
disease. Here, axonal accumulations of aggregated hun-
tingtin result in transport defects that precede neuronal
cell death (Li et al. 2001).
In AD, Aβ has been identified as one of the main medi-
ators of axonal degeneration (Yankner et al. 1990;E m r e
et al. 1992). In vitro, the exposure of cultured rat sympa-
thetic neurons to Aβ induces axonal degeneration, which
only in the second place triggers the activation of caspases
and subsequent neuronal cell death. This observation sup-
ports the hypothesis of primary axonal degeneration as
being an important step in the pathogenesis of AD. In vivo,
the clear spatial association of axonal swellings and dystro-
phic neurites with amyloid plaques points to a causal
relationship between Aβ and axonal degeneration (Stokin
et al. 2005). Transcranial two-photon imaging in vivo has
been able to visualize dendritic damage by amyloid deposits
near neurites; such damage leads to spine loss, shaft atrophy,
varicosity formation and finally continuity disruption (Tsai
et al. 2004). This is further strengthened by studies demon-
strating that injections of Aβ in brains of normal rats can
induce neurodegeneration (Kowall et al. 1991; Frautschy
et al. 1991). However, this effect seems to be dependent
on the aggregation state of Aβ as some forms of Aβ do not
cause neurodegeneration, whereas the fibrillar form seems
to be most neurotoxic (Podlisny et al. 1993; Snow et al.
1994). Interestingly, Aβ-mediated axonal toxicity can be
rescued by calpain inhibition, which in turn also prevents
apoptosis, suggesting a close interplay of amyloidogenic
proteins and calcium metabolism (Song et al. 2006).
Axonal transport
If we assume that axonal degeneration in traumatic or
degenerative disease is a mechanistically defined process,
then plausibly the disruption of a strategically important
entity, such as axonal transport, will ultimately result in
malfunction. Because of their enormous length in relation
to the cell soma, axons rely on an efficient transport system
to target proteins and organelles to specific compartments,
such as synaptic terminals or nodes of Ranvier. Deficiencies
in axonal transport have been visualized in various models
mimicking neurodegenerative disorders, such as motoneu-
ron disease, PD, Alzheimer’s dementia, Huntington’s
disease and Charcot-Marie-Tooth disease (for reviews, see
De Vos et al. 2008; Morfini et al. 2009).
Axonal transport is mediated by two major groups of
proteins: the kinesins, which mediate anterograde transport,
and the dyneins, which are responsible for the retrograde
counterpart. Mice expressing the mutant kinesin superfam-
ily member KIF1Bβ show transport defects for synaptic
vesicles and progressive muscle weakness attributable to a
peripheral neuropathy. In humans, mutations in the KIF1B
gene have been found in patients with a hereditary poly-
neuropathy (Charcot-Marie-Tooth disease, type 2A; Zhao
et al. 2001). Transport defects induced by mutations in
kinesin light-chain-1 can also activate stress kinases, such
as c-Jun-N-terminal kinase (see Kinase activation), and this
again can result in abnormal phosphorylation and aggregation
of tau (Falzone et al. 2009). Expectedly, retrograde transport
defects are no less relevant; missense point mutations in the
dynein heavy-chain induce motoneuron degeneration in
heterozygous mice and, in homozygous animals, the forma-
tion of inclusion bodies has been observed (Hafezparast
2003). Dynein mutations might also be a link to axonal
degeneration in motoneuron disease, as a recent study nicely
connects axonal transport deficits to autophagic impairment
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(Ravikumar et al. 2005).
Deficits in axonal transport are also key pathophysiolog-
ical features in AD and several publications support the
hypothesis that the disturbed axonal transport in AD is
either directly or indirectly caused by Aβ (see also
Alzheimer’s disease and Aggregation above). For example,
accumulations of APP as an indicator of disturbed axonal
transport have been found in a subset of axons in
TgCRND8/YFP-H mice and alterations in mitochondrial
transport have been visualized in TgCRND8/YFP-H/Mito
triple transgenics. However, the morphology of the mito-
chondria suggests rather a partial block than a complete
breakdown, which might be correlated with the chronic
development of pathology in this model (Adalbert et al.
2009). In another study, intracellular oligomeric Aβ inhibits
bidirectional axonal transport via the activation of endoge-
nous casein kinase 2 (Pigino et al. 2009). Application of
pharmacological inhibitors of casein kinase 2 is able to
prevent the impairment of axonal transport by oligomeric
Aβ. The presence of transport deficits has been also dem-
onstrated in vivo, manganese-enhanced magnetic resonance
imaging (MRI) being used in the Tg2576 mouse model of
AD to assess axonal transport. In young mice, before Aβ
deposition, axonal transport rates have been shown to be
normal. After the increase of Aβ deposition in aged mice,
however, a significant decrease in axonal transport rates is
observed compared with age-matched control animals
(Smith et al. 2007). Not only Aβ, but also tau seem to play
an important role in maintaining axonal transport and axonal
integrity. Crossing two mouse mutant strains, one of them
overexpressing mutated human APP and the other having a
knock-out of tau, results in the extensive formation of axo-
nal spheroids and a degeneration of neurites. This is inde-
pendent of Aβ plaques indicating a crucial function of tau
for the maintenance of axonal integrity (Dawson et al.
2010). Furthermore, a local axonal increase in tau concen-
tration has been shown to promote cargo detachment from
microtubules, whereas a decrease allows the uninterrupted
transport of cargos (Ebneth et al. 1998; Stamer et al. 2002;
Vershinin et al. 2007). In spite of this large body of data, the
exact interplay between tau and Aβ in the promotion of
axonal degeneration is not yet understood in detail.
Taken together, the data provide strong evidence that
axonal transport impairment contributes at least to axonal
dystrophy, which can, in the end, culminate in axonal de-
generation attributable to deficient cargo exchange. A direct
visualization of transport impairment, axonal dystrophy and
consecutive degeneration by live-imaging methods should
certainly strengthen this hypothesis. The finding that axonal
transport is gradually impaired in chronic disease and does
not immediately result in axonal degeneration offers an
especially challenging possibility for putative therapeutic
interventions, as the pathology might still be partially
reversible. Nevertheless, a process as complex as axonal
transport is unlikely to be rescued by one specific interven-
tion. In terms of pharmacological intervention, factors mod-
ulating axonal transport further upstream, such as protein
aggregation (Aggregation above), calpain-activation
(Calcium-triggered events) and the activation of c-Jun-N-
terminal kinase (JNK; Kinase activation) might be more
promising targets.
Kinase activation
Kinases participate in a specific manner in the execution of
the axonal destruction program. A few prominent examples
shall therefore be discussed in detail here without an attempt
to be comprehensive.
The JNKs are known as stress-activated protein kinases
because their activities typically increase in response to
Various cellular environmental stresses such as osmotic
stress, redox stress or irradiation (fro reviews, see Davis
2000; Weston and Davis 2007). Once activated by a stress
response or by inflammatory cytokines, they can propagate
the signal to induce cellular apoptosis (Kyriakis and Avruch
1996; Ip and Davis 1998). Injury can also activate axonally
located JNKs, resulting in axonal transport defects (see
Axonal transport) that are associated with the dissociation
of heavy-chain kinesin family-5B (KIF5B) protein from
tubulin in axons finally leading to increased degeneration
(Stagi et al. 2006). For example, activated phospho-JNK has
been found to be highly expressed in the lesioned cortico-
spinal tract in a mouse spinal cord injury model and axonal
retraction can be inhibited by the application of a pan-JNK
inhibitor, which also improves functional recovery (Yoshi-
mura et al. 2011). Vice versa, mutations in the kinesin light-
chain-1 are found to result in the activation of JNK, which
colocalizes with hyperphosphorylated and accumulated tau
in dystrophic axons (Falzone et al. 2009).
As described in detail under Parkinson’s disease, axonal
degeneration is also one of the earliest pathological hall-
marks of PD (Duda et al. 2006). One of the most frequently
employed toxin models for PD, the MPTP mouse model,
shows only mild to no neuronal loss in the subacute intox-
ication paradigm. However, the function of dopaminergic
neurons, being most dependent on their axonal structures, is
significantly impaired (Fox and Brotchie 2010). Here, the
JNK pathway is activated via phosphorylated c-Jun in the
striatum and in the substantia nigra; this appears not to be
correlated with the loss of neuronal cell bodies but might
represent a response to damage/loss of axonal terminals
(Willesen et al. 2002), as has been corroborated by the
finding that c-Jun is activated in dopaminergic neurons from
PD patients. The same authors have shown that, in the acute
MPTP mouse model of PD, both JNK2 and JNK3, but not
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dopaminergic cell demise (Hunot et al. 2004). Different
JNK isoforms apparently have distinct functions, since
JNK2 and JNK3 seem not to participate in retrograde axonal
degeneration following 6-hydroxydopamine (6-OHDA)
lesion in mice; although the cell soma is protected in
JNK2/3 double-null mutants, the axons still degenerate
(Ries et al. 2008).
JNK can also be activated by the dual leucine kinase
(DLK) in axonal lesion models in Drosophila and mice.
Indeed, animals deficient for DLK show a delay in Waller-
ian degeneration after sciatic nerve transection and in a toxin
model of vincristine treatment (Miller et al. 2009). Activa-
tion and phosphorylation of JNK is delayed in WldS
explants suggesting that WldS protein expression regulates
JNK activation (Barrientos et al. 2011).
Kinases involved in inhibitory myelin signalling are also
involved in the regulation of axonal stability. Myelin-
derived inhibitory molecules, such as Nogo (the neurite
outgrowth inhibitor), myelin-associated glycoprotein or oli-
godendrocyte myelin glycoprotein confer their signal
through the trimeric NgR/p75/LINGO-1 or NgR/TROY/
LINGO-1 receptor complexes (for a review, see McDonald
et al. 2011) or, as has been recently identified, via the paired
Ig-like receptor B (Atwal et al. 2008). Downstream, Rho-
associated kinase (ROCK) integrates the signal from other
inhibitory receptors, such as ephrin and semaphorin (Gold-
berg et al. 2004; Goldshmit et al. 2006). Although this
signalling pathway has been mostly studied in paradigms
of impaired axonal regeneration, indications have been
found that this pathway also participates in triggering axonal
degeneration. For example, the blocking of Nogo-A signal-
ling is able to attenuate axonal degeneration in an EAE
mouse model (Karnezis et al. 2004).
A recent report has implicated the phosphoinositide 4-
kinase 2 alpha (Pi4k2a) in axonal stability. Knockout mice
for Pi4k2a develop a progressive neurological disease with
tremor, limb weakness, urinary incontinence and premature
mortality. Axonal degeneration in the spinal cord has been
found to be a major histological correlate of the symptoms,
whereas peripheral nerves appear essentially normal. Thus,
Pi4k2a signalling appears to be crucial for axonal integrity
and therefore Pi4k2a has been proposed as a candidate gene
for hereditary spastic paraplegia (Simons et al. 2009).
Autophagy and the ubiquitin-proteasome system
Degradation of proteins or even organelles occurs in a
homeostatic manner via several degradative routes, one
of them being autophagy. Autophagy is a collective
term and, in this text, we use it to refer to macro-
autophagy. Because autophagy is a highly conserved
and tightly regulated mechanism any disturbance (be it
an increase or a decrease) can result in cellular
dysfunction.
Following mechanical axonal damage in a crush model
of the optic nerve, an increased number of autophagosomes
has been observed in the vicinity of the lesion site and this is
dependent on calcium influx. Inhibition of autophagy
attenuates axonal degeneration in this model (Koch et al.
2010; Knöferle et al. 2010). Autophagy is also induced in
degenerating neurites of sympathetic neurons in an axotomy
model, as has been substantiated by an accumulation of
autophagosomes and increased expression of LC3-II (a 16-
kDa protein that localizes to autophagosomal membranes).
Treatment with 3-methyladenine (3-MA) and knockdown of
autophagy-regulator 7 (Atg7) or Beclin1 are able to coun-
teract the degenerative process partially (Yang et al. 2007).
Cerebellar Purkinje cells show an induction of autophagy in
axon terminals upon excitotoxicity, with the process appear-
ing to be axon-specific and independent of the cell body
(Yue 2007). This has also been elegantly shown in a green
fluorescent protein (GFP)-LC3 transgenic mouse strain
crossed with the Lurcher mutant strain, in which a mutant
glutamate receptor is constitutively activated and causes
Next to autophagy-mediated degradation, the ubiquitin-
proteasome system (UPS) has also been shown to be rele-
vant for axonal degeneration. This has been demonstrated
by the inhibition of UPS in an optic nerve crush lesion
model in which Wallerian degeneration is attenuated by
proteasome inhibition. Fragmentation of microtubuli as an
early event following crush lesion can be diminished by the
application of the proteasome inhibitor MG132 (Zhai et al.
2003). On the other hand, proteasome inhibition by lacta-
cystin causes a dying-back-like degeneration in PC12 cells
in vitro (Laser et al. 2003). Thus, a disturbance of protea-
some function in one way or another can have detrimental
effects, similar to alterations in autophagy.
Therapeutic targets
Axonal membrane integrity
Structural lesions, such as the disruption of the axonal
membrane and microtubule breakage, are the primary events
in trauma-induced axonal degeneration and thus could
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Purkinje cell degeneration. Here, GFP-LC3-labelled auto-
phagosomes accumulate in axonal dystrophic swellings (Q.
J. Wang et al. 2006). Recently, an in-depth examination of
four different mouse models of nigrostriatal axon injury has
revealed the presence of ultrastructural features of autoph-
agy, such as autophagic vacuoles, in the degenerating neu-
rites. Autophagic puncta are induced proximally and distally
of the mechanical lesion site and in a striatal 6-OHDA
injection model (Cheng et al. 2011).represent early therapeutic targets. For example, axolemmal
pores, which are thought to be responsible for calcium
influx in diffuse axonal injury after brain trauma, can be
successfully treated in vitro with Poloxamer 188, a triblock
polymer, which is able to reseal membrane pores (Kilinc
et al. 2009). The hydrophilic polymer polyethylene glycol
(PEG) has similar chemical properties with regard to mem-
brane sealing (Shi and Borgens 2000). The application of
PEG-decorated silica nanoparticles in a spinal cord lesion
model in vivo results in an accumulation of the particles at
the lesion site and the recovery of electrical conduction
through the lesion site (Cho et al. 2010). Whether such
approaches will be applied in future clinical treatments will
largely depend on the feasibility of rapid application follow-
ing injury, targeted delivery to the lesion site and their side-
effects profile.
Inhibitors of calcium and calcium-dependent enzymes
Calcium influx inhibition, for example by L-type calcium
channel blockers such as nifedipine or nimodipine, is highly
protective in axonal lesion models in vitro. Metal ions
substituting for calcium, such as cobalt and manganese,
are also able to attenuate axonal degeneration in this model
(George et al. 1995). In the optic nerve crush model in vivo,
the application of a mixture of amlodipin, amiloride and
NBQX (2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo[f]qui-
noxaline-2,3-dione) prevents the increase of intra-axonal
calcium and consecutive axonal destruction. In reverse, the
disintegration of the axon is dramatically increased after the
addition of the calcium ionophore A23187 to the lesion site
(Knöferle et al. 2010). Inhibition of calcium influx by the N-
type-specific calcium channel blocker omega-conotoxin
GVIA is also axonoprotective in a rat model of autoimmune
optic neuritis (Gadjanski et al. 2009).
Inhibitors of calpains have been used as a successful
strategy to attenuate axonal damage in several models in
vitro and in vivo. For example, dorsal root ganglion axons
are protected by calpain inhibitors from axotomy-induced
axonal degeneration in vitro (George et al. 1995) and from
acute axonal degeneration in the spinal cord in vivo
(Kerschensteiner et al. 2005). Calpain inhibition has been
shown to be protective in models of traumatic brain injury; it
successfully prevents axonal beading after shear stress
(Kilinc et al. 2009) and is also protective in a model of
anoxic axonal damage (Jiang and Stys 2000). After fluid
percussion injury, the application of the calpain inhibitor
MDL-28170 exhibits protective effects against axonal
destruction. As might be expected from the disease mecha-
nism, earlier administration of the drug shows a better
axonoprotection than application at a later time point with
the best results being achieved when MDL-28170 is admin-
istered before lesion (Ai et al. 2007). Interestingly, both
studies have demonstrated only partial functional recovery,
suggesting that calpain is not the only calcium-dependent
downstream target and that other evasive pathways might
have been initiated at the same time. Thus, even calpain
inhibition may lie too far downstream in terms of functional
rescue.
Although the inhibition of calcium influx or intra-axonal
calcium release appears to be one of the most potent
approaches in the prevention of further degeneration, the
kinetics of calcium flux render calcium an unfavourable
target for therapeutic interventions in acute lesions. Calcium
influx in traumatic lesions usually occurs so fast that a
timely intervention appears unrealistic (Knöferle et al.
2010). However, the targeting of calcium could be benefi-
cial in chronic disorders, which have a much slower pro-
gression, and this is supported, for example, by the EAE
model data. Indeed, riluzole, the only drug licensed for the
treatment of ALS, acts as an NMDA receptor antagonist and
thus regulates calcium influx to the cell, a possible expla-
nation for its beneficial effects in this motoneuron disorder
(Van Damme et al. 2005). Interestingly, recent data from a
retrospective Danish population-based study employing lo-
gistic regression analysis suggest that subjects prescribed
dihydropyridines are less likely to develop PD; this indi-
cates a possible neuroprotective role for these centrally
acting L-type calcium channel blockers (Ritz et al. 2010).
Evidence is thus accumulating that calcium can also be a
target in chronic neurodegenerative disorders, a finding that
is of special interest, because many calcium channel block-
ers have well-known pharmacokinetics in humans and are
already widely used in clinical practice.
WldS/NMNAT
The WldS mutation has been shown to be neuroprotective in
several models of chronic degenerative CNS disease such as
PD, glaucoma, MS, Charcot-Marie-Tooth disease 1A and
axonal dystrophy (Mi et al. 2005; Kaneko et al. 2006;
Hasbani and O’Malley 2006; Howell et al. 2007; Wilbrey
et al. 2008; Beirowski et al. 2008; Meyer zu Horste et al.
2011). In a recent study evaluating various models of PD,
the WldS mutation is protective in anterograde but not
retrograde degeneration suggesting that both processes
involve different molecular mechanisms (Cheng and Burke
2010).
Further analysis of the biologically effective mechanism
of WldS has revealed that the enzymatic activity of
NMNAT1 together with the VCP-binding site of UBE4b
are required to achieve the full neuroprotective effect com-
parable to WldS-expression (Avery et al. 2009; Conforti
et al. 2009; Yahata et al. 2009). However, in Drosophila,
the overexpression of NMNAT3, an isoform of NMNAT
that localizes primarily to the cytosol and mitochondria,
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WldS. This shows not only the potential therapeutic value
of NMNAT3 in treating degenerative disease, but also the
importance of the subcellular localization of the active sub-
strate. Complete loss of NMNAT causes severe axonal
degeneration in Drosophila sensory neurons supporting its
essential role in the maintenance of axonal and dendritic
integrity (Wen et al. 2011). Consistently, axonally targeted
NMNAT1 is highly axonoprotective in a mouse model of
Wallerian degeneration, although the precise mechanism of
action is still under debate (Babetto et al. 2010).
Kinases
The diversity among kinases is reflected in the plethora of
pharmacological kinase inhibitors available. Here, we focus
on a few examples, namely inhibitors of ROCK, JNK, GSK-
3 and IkappaB (IκB), for which particular axonoprotective
effects have been described.
Interference with ROCK function has recently been
shown to be beneficial in various disease models as it is
able to confer neuroprotection and promote axonal regener-
ation (Lingor et al. 2008; Tönges et al. 2011). However,
evidence has also been obtained that ROCK inhibition pro-
tects from axonal degeneration. When axons are mechani-
cally severed, they retract because of increased actomyosin
contractility. This is based on the regulation of myosin II by
myosin light-chain kinase (MLCK), which directly phos-
phorylates myosin regulatory light chains and activates
myosin motor activity. Activated ROCK increases the phos-
phorylation of myosin regulatorylight chainsand additionally
inhibits myosin light-chain phosphatase by phosphorylation.
Itpossiblyevendirectlyphosphorylatesthemyosinregulatory
light chains themselves (Luo 2000). In an in vitro-approach,
the application of the pharmacological ROCK inhibitor Y-
27632 to severed chicken retinal axons has been shown
to inhibit myosin light-chain phosphorylation and there-
by significantly decreases the axonal retraction distance
(Gallo 2004).
In a mouse model of EAE, both the parenteral and oral
administration of the ROCK inhibitor fasudil prevents the
development of EAE induced by proteolipid protein. In
addition to a reduction of the specific proliferation of lym-
phocytes, a downregulation of interleukin (IL)-17 and a
marked decrease of the interferon-gamma/IL-4 ratio, CNS
demyelination and acute axonal transections are robustly
attenuated (Sun et al. 2006). This protection from axonal
degeneration has been confirmed by a study in a rat model
of experimental autoimmune neuritis (EAN)in which
ROCK inhibition can even reduce EAN severity when ad-
ministered after disease onset. Again, inflammatory cell
infiltration is markedly decreased and the secretion of
inflammatory cytokines is reduced (Pineda et al. 2011).
The mechanisms of action of ROCK inhibition with regard
to the attenuation of axonal degeneration thus seem to be
manifold and at least partially mediated via the modulation
of inflammatory processes and interference with cytoskele-
ton motility.
JNKs have been proposed as therapeutic targets for sev-
eral neurodegenerative disorders. However, in addition to
their neuroprotective action, experimental evidence now
suggests that JNK inhibition protects degenerating axons.
For example, the application of SP600125, a pan-JNK in-
hibitor, attenuates axonal retraction after spinal cord lesion
and improves the motor outcome (Yoshimura et al. 2011). A
shortcoming of JNK inhibition as a therapeutic approach
might be the broad range of JNK-mediated effects, which
result from the association of JNKs with other proteins in a
variety of signalosomes. Here, a selective targeting of JNKs
will not be sufficient but will require peptides that block
molecular domains of such JNK signalling complexes
(Waetzig and Herdegen 2005).
Finally, in a recent large scale screen of 480 bioactive
compounds, inhibitors of GSK-3 and IκB kinase have been
found to delay the fragmentation of severed axons markedly
in vitro. This has been verified by short-hairpin- RNA-
mediated knock-down of these target genes (Gerdts et al.
2011). Although this data has to be verified in vivo, these
kinases might represent novel pharmacological targets in
axonal degeneration.
From a therapeutic perspective, kinase inhibitors are prom-
ising substances and several drugs have already been licensed
for human use, mostly in the field of anti-cancer therapy.
Because kinase inhibitors are usually not completely specific,
target selectivity will be a major criterion in the selection
process when it comes to therapeutic considerations.
Autophagy
The therapeutic range of pharmacological approaches regu-
lating autophagy appears to be narrow because a basal level
of autophagy is essential for all cells, whereas slight shifts of
this equilibrium in either direction might cause pathology
(for excellent reviews, see Chu et al. 2009; Jaeger and
Wyss-Coray 2009).
For acute axonal degeneration in the rat optic nerve in
vivo, we have been able to show a clear axon stabilizing
effect of autophagy inhibition with 3-MA, suggesting that
autophagy inhibition in the early phase after a traumatic
nerve injury might be beneficial (Knöferle et al. 2010). This
protective effect on neurite integrity has also been found by
several other groups in other in vitro models: the inhibition
of autophagy by small molecules or siRNA results in atten-
uated neurite degeneration and increases cell viability in a
growth-factor-deprivation model in mouse superior cervical
ganglion neurons (Yang et al. 2007). In agreement, Atg7
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tion in the first 12 h following axonal transection in the same
cell culture model. Similarly, autophagy inhibition in Atg7
knock-out mice results in protection from neuron death and
axonal degeneration in a hypoxic-ischaemic injury model
(Koike et al. 2008).
On the other hand, autophagy seems to be neuroprotec-
tive under certain conditions depending on the phase and
form of axonal degeneration. For instance, in an in vivo
model of mouse traumatic brain injury, treatment with the
autophagy-inducing drug rapamycin significantly improves
functional recovery (Erlich et al. 2007) and similar results
have been obtained by other groups in related paradigms
(Egami et al. 2005; Sadasivan et al. 2008).
In chronic neurodegenerative disease models, therapeutic
modulation of autophagy in either direction has been shown
to be beneficial according to the specific model. For exam-
ple, activation of autophagy by the mTOR (mammalian
target of rapamycin) inhibitor rapamycin attenuates the
accumulation of mutant huntingtin and is neuroprotective
in a Drosophila model of Huntington’s disease (Ravikumar
et al. 2004). Conversely, application of the autophagy inhib-
itor 3-MA or knock-down of autophagy-regulators Atg5 or
Atg12 is neuroprotective in the MPP
+ and alpha-synuclein
(A53T) cell culture models of PD (Wong et al. 2011).
The regulation of autophagy in a therapeutic manner will
largely depend on increasing knowledge of the regulation of
this pathway in specific pathologies. Part of this improved
understanding must be a more detailed temporal resolution.
Autophagic flux might be increased at one point after lesion
but may return to normal levels or be inhibited at another. A
unidirectional approach, which does not take into account
the kinetics of autophagic activity, might therefore result in
unwanted detrimental effects by interference with this con-
served physiological mechanism.
Aggregation
The search for effective compounds or strategies to prevent
protein aggregation is one of the hottest topics in current
neurodegeneration research. Because of primary axonal
damage in the course of aggregopathies, this approach holds
the promise of achieving true neuroprotective and possibly
neurorestorative effects. One therapeutic approach that has
been tested extensively in AD mouse models is the immu-
nization of animals with antibodies against Aβ. In an APP
mutant mouse model (APPswe/PS1dE9), the application of
an anti-Aβ antibody has not only resulted in a modest
reduction of Aβ in the brain, but can also significantly
attenuate axonal degeneration resulting in higher axon den-
sities in the cortex and hippocampus of the treated mutant
mice (Liu et al. 2011). Targeting the aggregation of tau
seems similarly promising. Tau is a microtubule-associated
protein and both the loss and the toxic gain of function plus
the hyperphosphorylation and aggregation of tau have been
prime examples for aggregation-related axonal dystrophy
and degeneration, for example in AD. Oligomeric forms of
tau have been shown to impair fast axonal transport in vitro.
This effect can be attenuated by the addition of heat shock
protein 70 to oligomeric and fibrillar tau (Patterson et al.
2011). The use of drugs previously tested in human trials
and licensed for other pharmacological purposes is especial-
ly auspicious. In this context, immunophilin ligands such as
FK506 (an immunosuppressant that has been in clinical use
for more than 15 years) have recently showed remarkable
effects. FK506-binding protein (FKBP) family members
have previously been demonstrated to accelerate the aggre-
gation of alpha-synuclein in vitro. In a cell culture model of
synucleinopathy, FK506 has been shown to inhibit alpha-
synuclein aggregation and neuronal cell death. Similarly,
aggregate formation is reduced and cell viability is
improved after oral administration of FK506 in an AAV-
based mouse model of PD in vivo (Gerard et al. 2010).
Nevertheless, approaches involving interference with aggre-
gation will have to be carefully tuned in order to avoid
converse effects. An increase of toxic oligomeric species
at the cost of less fibril formation might result in exactly the
opposite outcome from that desired, as has been shown for
the disaccharide trehalose; although Aβ40 aggregation can
be inhibited by trehalose, the same treatment prevents only
the formation of fibrillar forms of Aβ42, toxic oligomeres
being still present and the toxicity of Aβ42 not being
attenuated (Liu et al. 2005).
Growth factors
Trophic factors exert an influence on growth, differentiation
and survival of neuronal populations during development
and in the adult. Because of their pleiotrophic effects, they
have not only been suggested as therapeutic agents for a
number of neurological disorders, but have already been
tested in human trials (e.g. Gill et al. 2003). Here, we will
review only a few prominent examples that have shown
protective effects in terms of axonal degeneration.
Viral vector-mediated overexpression of the neurotrophic
factor glial-cell-line derived neurotrophic factor (GDNF) in
the substantia nigra is able to improve axonal stability and
somatic survival of dopaminergic neurons in the 6-OHDA
model of PD. Thus, 6-OHDA-mediated axonal dying-back
pathology can be rescued, at least partially, by GDNF
(Mandel 1997). Kirik et al. (2000) have shown that GDNF
application to the striatum is required in this model in order
to protect the projecting nigrostriatal fibres. Thus, the loca-
tion of growth factor application needs to be considered
from a technical point of view. On the other hand, GDNF
is not sufficiently protective in a model of alpha-synuclein-
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are equally unprotected by lentiviral GDNF expression.
Corresponding to this finding, the expression of GDNF also
does not prevent the aggregation of alpha-synuclein in do-
paminergic terminals (Decressac et al. 2011). Lentiviral
vector application of GDNF is furthermore not protective
against axonal degeneration induced by the overexpression
of the human pathogenically mutated A30P alpha-synuclein
(Lo Bianco et al. 2004). All this makes clear that a growth
factor such as GDNF acts only on parts of the degenerative
cascade and a therapeutic effect in humans will be limited if
major pathomechanisms, such as aggregation, are not suffi-
ciently addressed. Axonal transport deficits might also be
responsible for the limited effect of growth factor therapy in
human PD patients, because the trophic factors are not
sufficiently transported to the cell soma. For example, stria-
tal delivery of AAV-neurturin will require much longer
retrograde transport in humans than in experimental models
involving smaller mammals, i.e. non-human primates or
rodents (Bartus et al. 2011).
In an axotomy model, local application of ciliary neuro-
trophic factor is able to prevent the degeneration of rat facial
motoneurons (Sendtner et al. 1990) and a more recent report
presents data on ciliary neurotrophic factor (CNTF)-mediated
protection in axonal pruning of motoneurons in the SOD1
(G93A) mouse model (Pun et al. 2006). Here, the stalling of
synapticvesicleshas beenidentified asanearly signofaxonal
dysfunctionandtheapplicationofCNTFisabletoreversethis
pathology,whereasGDNFdoesnot.Axonaldie-backinduced
by axotomy of the optic nerve can be inhibited by the local
application of brain-derived neurotrophic factor and also by
neurotrophin-3 and CNTF (Weibel et al. 1995).
Erythropoietin (EPO) is a multifunctional cytokine that
not only controls erythropoiesis, but has also been attributed
neuroprotective properties (e.g. Grunfeld et al. 2007; Xue et
al. 2010; Reitmeir et al. 2011). Several studies in a model of
peripheral neuropathy (acrylamide-mediated axonal injury)
have demonstrated that EPO is the functional mediator of
NO-induced axonal protection and can be released by
Schwann cells upon injury. EPO signalling in this model is
dependent on the activation of hypoxia-inducible factor-1α
(Keswani et al. 2004, 2011).
Concluding remarks
The molecular machinery of axonal degeneration still
requires a much better understanding and this can be partially
achieved through in vivo visualization of the implicated pro-
cesses. Here, life-imaging techniques (Misgeld and Kerschen-
steiner 2006) and MRI methods (Ge 2006; Fox et al. 2011;
Kim et al. 2011) might yield more information and further
insights can be expected from the evolution of these methods
(Westphal etal. 2008).Because ofthe multitudeofaetiologies
and molecular mechanisms involved in axonal degeneration,
therapeutic approaches aimed at prevention or restitution will
probably require multiple strategies. Intriguingly, in spite of
the pathological diversity of axonal degeneration, some key-
stones of the degenerative cascade and thus some key targets
appeartobeidentical.Theregulationofaxonalcalciumlevels,
for example, is of major importance for acute and chronic
degenerative paradigms. On the other hand, the kinetics of
intra-axonal calcium levels represents a challenge when it
comes to a therapeutic application. Alterations of homeostatic
mechanisms, such as autophagy, are equally efficient in mod-
ulating axonal stability but therapeutic intervention appears to
depend on a narrow time window, outside of which any
interference with such essential cellular processes might lead
to detrimental instead of beneficial effects. Questions of ad-
ministration routes, tissue specific targeting, timing and dura-
tion are not discussed in this review but will have to be
considered with respect to the design of axonoprotective
therapies.
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